Software development and CDMO experts share their key tips for choosing the right digital technologies and partnerships Alexander Seyf Digital transformation is a key phrase buzzing among modern pharma companies. Although there can be benefits for any enterprise, cell and gene therapy manufacturing is, arguably, where companies stand to gain the most. This area of the industry continues to mature and needs every edge it can get to optimize manufacturing. However, the digital journey is not an easy one, which is why many companies turn to partnerships. Here, we speak with software expert Alexander Seyf, CEO and co-founder of Autolomous, and David Smith, VP of Development at CDMO BioCentriq, to get their take on the digital future of the sector and tips for success in choosing the right technologies and partnerships. How can advanced digital platforms benefit manufacturers? David Smith (DS): There are a number of points to highlight including reduced cost, faster response time, improved communication across stakeholders, robust chains of identity and custody, and improved efficiency and visibility on delivery times. Supply chain management interfacing digitally to the warehouse ensures stock levels are maintained based on usage – and even supplier stock levels. David Smith The difficult […]
Click here to view original web page at themedicinemaker.com
